Scalper1 News
Shares of biotech Zafgen (ZFGN) lost more than half their value Wednesday after the company reported a second death in its obesity-drug trial. Zafgen has been running an open-label extension study (in which all patients, including the former placebo group, knowingly go on a drug) of its drug beloranib as a treatment for Prader-Willi syndrome, a genetic disease that brings chronic hunger and overeating, among other things. The company reported that Scalper1 News
Scalper1 News